-
1
-
-
21344440247
-
Molecular classification and pathogenesis of eosinophilic disorders: 2005 update
-
Gotlib J. Molecular classification and pathogenesis of eosinophilic disorders: 2005 update. Acta Haematol 2005, 114:7-25.
-
(2005)
Acta Haematol
, vol.114
, pp. 7-25
-
-
Gotlib, J.1
-
2
-
-
33646245681
-
Eosinophilia: secondary, clonal and idiopathic
-
Tefferi A., Patnaik M.M., Pardanani A. Eosinophilia: secondary, clonal and idiopathic. Br J Haematol 2006, 133:468-492.
-
(2006)
Br J Haematol
, vol.133
, pp. 468-492
-
-
Tefferi, A.1
Patnaik, M.M.2
Pardanani, A.3
-
3
-
-
34548525771
-
Chronic eosinophilic leukemias and the myeloproliferative variant of the hypereosinophilic syndrome
-
Bain B.J., Fletcher S.H. Chronic eosinophilic leukemias and the myeloproliferative variant of the hypereosinophilic syndrome. Immunol Allergy Clin North Am 2007, 27:377-388.
-
(2007)
Immunol Allergy Clin North Am
, vol.27
, pp. 377-388
-
-
Bain, B.J.1
Fletcher, S.H.2
-
4
-
-
84892809487
-
Chronic eosinophilic leukemia/hypereosinophilic syndrome
-
Gotlib J. Chronic eosinophilic leukemia/hypereosinophilic syndrome. Cancer Treat Res 2008, 142:69-106.
-
(2008)
Cancer Treat Res
, vol.142
, pp. 69-106
-
-
Gotlib, J.1
-
5
-
-
67349151349
-
Pathogenesis, classification, and therapy of eosinophilia and eosinophil disorders
-
Valent P. Pathogenesis, classification, and therapy of eosinophilia and eosinophil disorders. Blood Rev 2009, 23:157-165.
-
(2009)
Blood Rev
, vol.23
, pp. 157-165
-
-
Valent, P.1
-
6
-
-
0344987881
-
A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome
-
Cools J., DeAngelo D.J., Gotlib J., et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med 2003, 348:1201-1214.
-
(2003)
N Engl J Med
, vol.348
, pp. 1201-1214
-
-
Cools, J.1
DeAngelo, D.J.2
Gotlib, J.3
-
7
-
-
1842474941
-
The FIP1L1-PDGFRalpha fusion tyrosine kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia: implications for diagnosis, classification, and management
-
Gotlib J., Cools J., Malone J.M., et al. The FIP1L1-PDGFRalpha fusion tyrosine kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia: implications for diagnosis, classification, and management. Blood 2004, 103:2879-2891.
-
(2004)
Blood
, vol.103
, pp. 2879-2891
-
-
Gotlib, J.1
Cools, J.2
Malone, J.M.3
-
8
-
-
0002884977
-
Chronic eosinophilic leukaemia and the idiopathic hypereosinophilic syndrome
-
IARC Press, Lyon, France, E.S. Jaffe, N.L. Harris, H. Stein (Eds.)
-
Bain B.J., Pierre R., Imbert M., et al. Chronic eosinophilic leukaemia and the idiopathic hypereosinophilic syndrome. The World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of Haemopoietic and Lymphoid Tissues 2001, 29-31. IARC Press, Lyon, France. E.S. Jaffe, N.L. Harris, H. Stein (Eds.).
-
(2001)
The World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of Haemopoietic and Lymphoid Tissues
, pp. 29-31
-
-
Bain, B.J.1
Pierre, R.2
Imbert, M.3
-
9
-
-
56249136000
-
Chronic eosinophilic leukaemia, not otherwise specified
-
IARC Press, Lyon, France, S.H. Swerdlow, E. Campo, N.L. Harris (Eds.)
-
Bain B.J., Gilliland D.G., Vardiman J.W., et al. Chronic eosinophilic leukaemia, not otherwise specified. WHO Classification of Tumours of Hematopoietic and Lymphoid Tissues 2008, 51-53. IARC Press, Lyon, France. S.H. Swerdlow, E. Campo, N.L. Harris (Eds.).
-
(2008)
WHO Classification of Tumours of Hematopoietic and Lymphoid Tissues
, pp. 51-53
-
-
Bain, B.J.1
Gilliland, D.G.2
Vardiman, J.W.3
-
10
-
-
0037596569
-
Discovery of a fusion kinase in EOL-1 cells and idiopathic hypereosinophilic syndrome
-
Griffin J.H., Leung J., Bruner R.J., et al. Discovery of a fusion kinase in EOL-1 cells and idiopathic hypereosinophilic syndrome. Proc Natl Acad Sci U S A 2003, 100:7830-7835.
-
(2003)
Proc Natl Acad Sci U S A
, vol.100
, pp. 7830-7835
-
-
Griffin, J.H.1
Leung, J.2
Bruner, R.J.3
-
11
-
-
1642324059
-
The EOL-1 cell line as an invitro model for the study of FIP1L1-PDGFRA-positive chronic eosinophilic leukemia
-
Cools J., Quentmeier H., Huntly B.J., et al. The EOL-1 cell line as an invitro model for the study of FIP1L1-PDGFRA-positive chronic eosinophilic leukemia. Blood 2004, 103:2802-2805.
-
(2004)
Blood
, vol.103
, pp. 2802-2805
-
-
Cools, J.1
Quentmeier, H.2
Huntly, B.J.3
-
12
-
-
33749983643
-
Activity of AMN107, a novel aminopyrimidine tyrosine kinase inhibitor, against human FIP1L1-PDGFR-alpha-expressing cells
-
Verstovsek S., Giles F.J., Quintás-Cardama A., et al. Activity of AMN107, a novel aminopyrimidine tyrosine kinase inhibitor, against human FIP1L1-PDGFR-alpha-expressing cells. Leuk Res 2006, 30:1499-1505.
-
(2006)
Leuk Res
, vol.30
, pp. 1499-1505
-
-
Verstovsek, S.1
Giles, F.J.2
Quintás-Cardama, A.3
-
13
-
-
38949217352
-
All-trans-retinoic acid enhances apoptosis induction by tyrosine kinase inhibitors in the eosinophilic leukemia-derived EoL-1 cell line
-
Robert C., Apàti A., Chomienne C., et al. All-trans-retinoic acid enhances apoptosis induction by tyrosine kinase inhibitors in the eosinophilic leukemia-derived EoL-1 cell line. Leuk Res 2008, 32:343-346.
-
(2008)
Leuk Res
, vol.32
, pp. 343-346
-
-
Robert, C.1
Apàti, A.2
Chomienne, C.3
-
14
-
-
52049122130
-
Dasatinib inhibits thegrowth and survival of neoplastic human eosinophils (EOL-1) through targeting of FIP1L1-PDGFRalpha
-
Baumgartner C., Gleixner K.V., Peter B., et al. Dasatinib inhibits thegrowth and survival of neoplastic human eosinophils (EOL-1) through targeting of FIP1L1-PDGFRalpha. Exp Hematol 2008, 36:1244-1253.
-
(2008)
Exp Hematol
, vol.36
, pp. 1244-1253
-
-
Baumgartner, C.1
Gleixner, K.V.2
Peter, B.3
-
15
-
-
84856832061
-
Nilotinib and imatinib are comparably effective in reducing growth of human eosinophil leukemia cells in a newly established xenograft model
-
Wicklein D., Ramos Leal N., Salamon J., et al. Nilotinib and imatinib are comparably effective in reducing growth of human eosinophil leukemia cells in a newly established xenograft model. PLoS One 2012, 7:e30567.
-
(2012)
PLoS One
, vol.7
-
-
Wicklein, D.1
Ramos Leal, N.2
Salamon, J.3
-
16
-
-
0038386031
-
Imatinib therapy for hypereosinophilic syndrome and other eosinophilic disorders
-
Pardanani A., Reeder T., Porrata L.F., et al. Imatinib therapy for hypereosinophilic syndrome and other eosinophilic disorders. Blood 2003, 101:3391-3397.
-
(2003)
Blood
, vol.101
, pp. 3391-3397
-
-
Pardanani, A.1
Reeder, T.2
Porrata, L.F.3
-
17
-
-
34249732053
-
Low-dose imatinib mesylate leads to rapid induction of major molecular responses and achievement of complete molecular remission in FIP1L1-PDGFRA-positive chronic eosinophilic leukemia
-
Jovanovic J.V., Score J., Waghorn K., et al. Low-dose imatinib mesylate leads to rapid induction of major molecular responses and achievement of complete molecular remission in FIP1L1-PDGFRA-positive chronic eosinophilic leukemia. Blood 2007, 109:4635-4640.
-
(2007)
Blood
, vol.109
, pp. 4635-4640
-
-
Jovanovic, J.V.1
Score, J.2
Waghorn, K.3
-
18
-
-
35348993411
-
The efficacy of imatinib mesylate in patients with FIP1L1-PDGFRalpha-positive hypereosinophilic syndrome. Results of a multicenter prospective study
-
Baccarani M., Cilloni D., Rondoni M., et al. The efficacy of imatinib mesylate in patients with FIP1L1-PDGFRalpha-positive hypereosinophilic syndrome. Results of a multicenter prospective study. Haematologica 2007, 92:1173-1179.
-
(2007)
Haematologica
, vol.92
, pp. 1173-1179
-
-
Baccarani, M.1
Cilloni, D.2
Rondoni, M.3
-
19
-
-
55949102355
-
Safety and efficacy of imatinib in chronic eosinophilic leukaemia and hypereosinophilic syndrome: a phase-II study
-
Metzgeroth G., Walz C., Erben P., et al. Safety and efficacy of imatinib in chronic eosinophilic leukaemia and hypereosinophilic syndrome: a phase-II study. Br J Haematol 2008, 143:707-715.
-
(2008)
Br J Haematol
, vol.143
, pp. 707-715
-
-
Metzgeroth, G.1
Walz, C.2
Erben, P.3
-
20
-
-
0346249716
-
The FIP1L1-PDGFRalpha kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia
-
Cools J., Stover E.H., Wlodarska I., et al. The FIP1L1-PDGFRalpha kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia. Curr Opin Hematol 2004, 11:51-57.
-
(2004)
Curr Opin Hematol
, vol.11
, pp. 51-57
-
-
Cools, J.1
Stover, E.H.2
Wlodarska, I.3
-
21
-
-
66849087150
-
FIP1L1-PDGFRalpha D842V, a novel panresistant mutant, emerging after treatment of FIP1L1-PDGFRalpha T674I eosinophilic leukemia with single agent sorafenib
-
Lierman E., Michaux L., Beullens E., et al. FIP1L1-PDGFRalpha D842V, a novel panresistant mutant, emerging after treatment of FIP1L1-PDGFRalpha T674I eosinophilic leukemia with single agent sorafenib. Leukemia 2009, 23:845-851.
-
(2009)
Leukemia
, vol.23
, pp. 845-851
-
-
Lierman, E.1
Michaux, L.2
Beullens, E.3
-
22
-
-
65549100146
-
A novel FIP1L1-PDGFRA mutant destabilizing the inactive conformation of the kinase domain in chronic eosinophilic leukemia/hypereosinophilic syndrome
-
Salemi S., Yousefi S., Simon D., et al. A novel FIP1L1-PDGFRA mutant destabilizing the inactive conformation of the kinase domain in chronic eosinophilic leukemia/hypereosinophilic syndrome. Allergy 2009, 64:913-918.
-
(2009)
Allergy
, vol.64
, pp. 913-918
-
-
Salemi, S.1
Yousefi, S.2
Simon, D.3
-
23
-
-
79952004905
-
The low frequency of clinical resistance to PDGFR inhibitors in myeloid neoplasms with abnormalities of PDGFRA might be related to the limited repertoire of possible PDGFRA kinase domain mutations invitro
-
von Bubnoff N., Gorantla S.P., Engh R.A., et al. The low frequency of clinical resistance to PDGFR inhibitors in myeloid neoplasms with abnormalities of PDGFRA might be related to the limited repertoire of possible PDGFRA kinase domain mutations invitro. Oncogene 2011, 30:933-943.
-
(2011)
Oncogene
, vol.30
, pp. 933-943
-
-
von Bubnoff, N.1
Gorantla, S.P.2
Engh, R.A.3
-
24
-
-
0142119964
-
PKC412 overcomes resistance to imatinib in a murine model of FIP1L1-PDGFRα-induced myeloproliferative disease
-
Cools J., Stover E.H., Boulton C.L., et al. PKC412 overcomes resistance to imatinib in a murine model of FIP1L1-PDGFRα-induced myeloproliferative disease. Cancer Cell 2003, 3:459-469.
-
(2003)
Cancer Cell
, vol.3
, pp. 459-469
-
-
Cools, J.1
Stover, E.H.2
Boulton, C.L.3
-
25
-
-
33747203008
-
Sorafenib is a potent inhibitor of FIP1L1-PDGFRalpha and the imatinib-resistant FIP1L1-PDGFRalpha T674I mutant
-
Lierman E., Folens C., Stover E.H., et al. Sorafenib is a potent inhibitor of FIP1L1-PDGFRalpha and the imatinib-resistant FIP1L1-PDGFRalpha T674I mutant. Blood 2006, 108:1374-1376.
-
(2006)
Blood
, vol.108
, pp. 1374-1376
-
-
Lierman, E.1
Folens, C.2
Stover, E.H.3
-
26
-
-
33745059630
-
The FIP1L1-PDGFRA T674I mutation can be inhibited by the tyrosine kinase inhibitor AMN107 (nilotinib)
-
von Bubnoff N., Gorantla S.P., Thöne S., et al. The FIP1L1-PDGFRA T674I mutation can be inhibited by the tyrosine kinase inhibitor AMN107 (nilotinib). Blood 2006, 107:4970-4971.
-
(2006)
Blood
, vol.107
, pp. 4970-4971
-
-
von Bubnoff, N.1
Gorantla, S.P.2
Thöne, S.3
-
27
-
-
84863782614
-
Ponatinib is active against imatinib-resistant mutants of FIP1L1-PDGFRA and KIT, and against FGFR1-derived fusion kinases
-
Lierman E., Smits S., Cools J., et al. Ponatinib is active against imatinib-resistant mutants of FIP1L1-PDGFRA and KIT, and against FGFR1-derived fusion kinases. Leukemia 2012, 26:1693-1695.
-
(2012)
Leukemia
, vol.26
, pp. 1693-1695
-
-
Lierman, E.1
Smits, S.2
Cools, J.3
-
28
-
-
0022360099
-
Establishment and characterization of a new human eosinophilic leukemia cell line
-
Saito H., Bourinbaiar A., Ginsburg M., et al. Establishment and characterization of a new human eosinophilic leukemia cell line. Blood 1985, 66:1233-1240.
-
(1985)
Blood
, vol.66
, pp. 1233-1240
-
-
Saito, H.1
Bourinbaiar, A.2
Ginsburg, M.3
-
29
-
-
0032530972
-
Transformation of hematopoietic cell lines to growth-factor independence and induction of a fatal myelo- and lymphoproliferative disease in mice by retrovirally transduced TEL/JAK2 fusion genes
-
Schwaller J., Frantsve J., Aster J., et al. Transformation of hematopoietic cell lines to growth-factor independence and induction of a fatal myelo- and lymphoproliferative disease in mice by retrovirally transduced TEL/JAK2 fusion genes. EMBO J 1998, 17:5321-5333.
-
(1998)
EMBO J
, vol.17
, pp. 5321-5333
-
-
Schwaller, J.1
Frantsve, J.2
Aster, J.3
-
30
-
-
0036373335
-
Morphological and biochemical aspects of apoptosis, oncosis and necrosis
-
Van Cruchten S., Van Den Broeck W. Morphological and biochemical aspects of apoptosis, oncosis and necrosis. Anat Histol Embryol 2002, 31:214-223.
-
(2002)
Anat Histol Embryol
, vol.31
, pp. 214-223
-
-
Van Cruchten, S.1
Van Den Broeck, W.2
-
31
-
-
84856396314
-
The PI3-kinase/mTOR-targeting drug NVP-BEZ235 inhibits growth and IgE-dependent activation of human mast cells and basophils
-
Blatt K., Herrmann H., Mirkina I., et al. The PI3-kinase/mTOR-targeting drug NVP-BEZ235 inhibits growth and IgE-dependent activation of human mast cells and basophils. PLoS One 2012, 7:e29925.
-
(2012)
PLoS One
, vol.7
-
-
Blatt, K.1
Herrmann, H.2
Mirkina, I.3
-
32
-
-
84862024642
-
NI-1: a novel canine mastocytoma model for studying drug resistance and IgER-dependent mast cell activation
-
Hadzijusufovic E., Peter B., Herrmann H., et al. NI-1: a novel canine mastocytoma model for studying drug resistance and IgER-dependent mast cell activation. Allergy 2012, 67:858-868.
-
(2012)
Allergy
, vol.67
, pp. 858-868
-
-
Hadzijusufovic, E.1
Peter, B.2
Herrmann, H.3
-
33
-
-
0024323740
-
Recombinant human interleukin 5 is a selective eosinophil chemoattractant
-
Wang J.M., Rambaldi A., Biondi A., et al. Recombinant human interleukin 5 is a selective eosinophil chemoattractant. Eur J Immunol 1989, 19:701-705.
-
(1989)
Eur J Immunol
, vol.19
, pp. 701-705
-
-
Wang, J.M.1
Rambaldi, A.2
Biondi, A.3
-
34
-
-
0029836124
-
Eotaxin triggers eosinophil-selective chemotaxis and calcium flux via a distinct receptor and induces pulmonary eosinophilia in the presence of interleukin 5 in mice
-
Rothenberg M.E., Ownbey R., Mehlhop P.D., et al. Eotaxin triggers eosinophil-selective chemotaxis and calcium flux via a distinct receptor and induces pulmonary eosinophilia in the presence of interleukin 5 in mice. Mol Med 1996, 2:334-348.
-
(1996)
Mol Med
, vol.2
, pp. 334-348
-
-
Rothenberg, M.E.1
Ownbey, R.2
Mehlhop, P.D.3
-
35
-
-
84878089990
-
Oncostatin M is a FIP1L1/PDGFRA-dependent mediator of cytokine production in chronic eosinophilic leukemia
-
Hoermann G., Cerny-Reiterer S., Sadovnik I., et al. Oncostatin M is a FIP1L1/PDGFRA-dependent mediator of cytokine production in chronic eosinophilic leukemia. Allergy 2013, 68:713-723.
-
(2013)
Allergy
, vol.68
, pp. 713-723
-
-
Hoermann, G.1
Cerny-Reiterer, S.2
Sadovnik, I.3
-
36
-
-
84863805992
-
Pathogenesis and classification of eosinophil disorders: a review of recent developments in the field
-
Valent P., Gleich G.J., Reiter A., et al. Pathogenesis and classification of eosinophil disorders: a review of recent developments in the field. Expert Rev Hematol 2012, 5:157-176.
-
(2012)
Expert Rev Hematol
, vol.5
, pp. 157-176
-
-
Valent, P.1
Gleich, G.J.2
Reiter, A.3
-
37
-
-
84870012939
-
Ponatinib in refractory Philadelphia chromosome-positive leukemias
-
Cortes J.E., Kantarjian H., Shah N.P., et al. Ponatinib in refractory Philadelphia chromosome-positive leukemias. N Engl J Med 2012, 367:2075-2088.
-
(2012)
N Engl J Med
, vol.367
, pp. 2075-2088
-
-
Cortes, J.E.1
Kantarjian, H.2
Shah, N.P.3
|